| Name | Title | Contact Details |
|---|
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
Segetis, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CARIS MPI is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UNIConnect LC is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NeuroVasc Technologies is a developer of mechanical thrombectomy solutions for revascularization of the brain.